Sanofi, Dabur Patent Dispute Over Eloxatin Survives

Law360, New York (March 19, 2010, 3:40 PM EDT) -- A federal judge has denied opposing summary judgment motions for plaintiff Sanofi-Aventis US LLC and defendants Fresenius Kabi Oncology PLC and Dabur Pharma Ltd. in an infringement suit over two patents related to the popular colon cancer drug Eloxatin.

Judge Joel A. Pisano of the U.S. District Court for the District of New Jersey on Thursday denied the defendants' motion for summary judgment on U.S. Patent Numbers 5,716,988 and 5,290,961, and also denied Sanofi's cross-motion for summary judgment of infringement as to the '961 patent....
To view the full article, register now.